BR112012010333A2 - peptídeos terapêuticos - Google Patents
peptídeos terapêuticosInfo
- Publication number
- BR112012010333A2 BR112012010333A2 BR112012010333A BR112012010333A BR112012010333A2 BR 112012010333 A2 BR112012010333 A2 BR 112012010333A2 BR 112012010333 A BR112012010333 A BR 112012010333A BR 112012010333 A BR112012010333 A BR 112012010333A BR 112012010333 A2 BR112012010333 A2 BR 112012010333A2
- Authority
- BR
- Brazil
- Prior art keywords
- substitution
- groups
- amino acid
- group
- cyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0919194.1A GB0919194D0 (en) | 2009-11-02 | 2009-11-02 | Compounds |
| PCT/GB2010/002024 WO2011051692A1 (en) | 2009-11-02 | 2010-11-02 | Therapeutic peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012010333A2 true BR112012010333A2 (pt) | 2016-03-29 |
Family
ID=41435032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012010333A BR112012010333A2 (pt) | 2009-11-02 | 2010-11-02 | peptídeos terapêuticos |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8809280B2 (enExample) |
| EP (1) | EP2496596B1 (enExample) |
| JP (1) | JP5810090B2 (enExample) |
| KR (1) | KR101730680B1 (enExample) |
| CN (1) | CN102762586B (enExample) |
| AU (1) | AU2010311186B2 (enExample) |
| BR (1) | BR112012010333A2 (enExample) |
| CA (1) | CA2777749C (enExample) |
| DK (1) | DK2496596T3 (enExample) |
| ES (1) | ES2621188T3 (enExample) |
| GB (1) | GB0919194D0 (enExample) |
| NZ (1) | NZ599791A (enExample) |
| PL (1) | PL2496596T3 (enExample) |
| RU (2) | RU2548905C2 (enExample) |
| WO (1) | WO2011051692A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3974563A1 (en) | 2011-12-28 | 2022-03-30 | Chugai Seiyaku Kabushiki Kaisha | Cyclic peptides |
| JP7020910B2 (ja) | 2015-03-13 | 2022-02-16 | 中外製薬株式会社 | 改変アミノアシルｔＲＮＡ合成酵素およびその用途 |
| GB201601868D0 (en) | 2016-02-02 | 2016-03-16 | Lytix Biopharma As | Methods |
| CN109071600A (zh) * | 2016-04-14 | 2018-12-21 | 道健康生活医药株式会社 | 淀粉样蛋白球体（aspd）结合抑制肽以及评价和筛选方法 |
| WO2018143145A1 (ja) | 2017-01-31 | 2018-08-09 | 中外製薬株式会社 | 無細胞翻訳系におけるペプチドの合成方法 |
| GB201705255D0 (en) * | 2017-03-31 | 2017-05-17 | Univ I Tromsø - Norges Arktiske Univ | Bioactive cyclic compounds |
| WO2018188761A1 (en) | 2017-04-13 | 2018-10-18 | Lytix Biopharma As | Method of reducing population size of tregs and/or mdscs |
| US11542299B2 (en) | 2017-06-09 | 2023-01-03 | Chugai Seiyaku Kabushiki Kaisha | Method for synthesizing peptide containing N-substituted amino acid |
| JP7411414B2 (ja) | 2017-12-15 | 2024-01-11 | 中外製薬株式会社 | ペプチドの製造方法、及び塩基の処理方法 |
| KR20250119653A (ko) | 2018-11-07 | 2025-08-07 | 추가이 세이야쿠 가부시키가이샤 | O-치환 세린 유도체의 제조 방법 |
| EP3889164A4 (en) | 2018-11-30 | 2022-11-02 | Chugai Seiyaku Kabushiki Kaisha | METHOD FOR DEPROTECTION AND METHOD FOR RESIN REMOVAL IN A SOLID PHASE REACTION OF A PEPTIDE COMPOUND OR AN AMIDE COMPOUND, AND METHOD FOR PRODUCTION OF A PEPTIDE COMPOUND |
| JP7472101B2 (ja) | 2019-03-15 | 2024-04-22 | 中外製薬株式会社 | 芳香族アミノ酸誘導体の製造方法 |
| CN110294793B (zh) * | 2019-06-24 | 2023-10-27 | 合肥科生景肽生物科技有限公司 | Sumo荧光探针及其制备方法 |
| JP6880352B1 (ja) | 2019-11-07 | 2021-06-02 | 中外製薬株式会社 | Ｋｒａｓ阻害作用を有する環状ペプチド化合物 |
| CN114790151B (zh) * | 2022-02-14 | 2023-03-31 | 湖南省湘中制药有限公司 | 一种2-氰基-2-丙戊酸甲酯的复合催化制备方法 |
| KR20250122523A (ko) | 2022-12-20 | 2025-08-13 | 리틱스 바이오파마 에이에스 | 종양 용해성 펩티드 및 키토산을 포함하는 조성물 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4342705A (en) | 1979-11-23 | 1982-08-03 | Monsanto Company | Methylene thioethers |
| AU565221B2 (en) | 1982-06-03 | 1987-09-10 | Montedison S.P.A. | 2-(1,2,4-triazol-1-yl) propanone derivatives |
| IT1161927B (it) | 1983-03-31 | 1987-03-18 | Montedison Spa | Furano-derivati ad attivita' fungicida |
| DK523288A (da) | 1987-10-06 | 1989-04-07 | Hoffmann La Roche | Aminosyrederivater |
| CA1328333C (en) | 1988-03-04 | 1994-04-05 | Quirico Branca | Amino acid derivatives |
| CA2088195A1 (en) | 1990-08-31 | 1992-03-01 | David C. Horwell | Cholecystokinin antagonists, their preparation and therapeutic use |
| US5593967A (en) | 1990-08-31 | 1997-01-14 | Warner-Lambert Company | Cholecystokinin antagonists, their preparation and therapeutic use |
| US5387671A (en) * | 1990-12-27 | 1995-02-07 | Abbott Laboratories | Hexa- and heptapeptide anaphylatoxin-receptor ligands |
| US5885782A (en) | 1994-09-13 | 1999-03-23 | Nce Pharmaceuticals, Inc. | Synthetic antibiotics |
| CZ297544B6 (cs) | 1996-01-02 | 2007-02-07 | Aventis Pharmaceuticals Inc. | Substituované N-[(aminoiminomethyl)-fenyl]propylamidy nebo N-[(aminomethyl)fenyl]propylamidy |
| US6323227B1 (en) | 1996-01-02 | 2001-11-27 | Aventis Pharmaceuticals Products Inc. | Substituted N-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides |
| US6080767A (en) | 1996-01-02 | 2000-06-27 | Aventis Pharmaceuticals Products Inc. | Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides |
| JP3734907B2 (ja) | 1996-12-19 | 2006-01-11 | 富士写真フイルム株式会社 | 現像処理方法 |
| DE102006018080A1 (de) | 2006-04-13 | 2007-10-18 | Aicuris Gmbh & Co. Kg | Lysobactinamide |
| JP5322108B2 (ja) * | 2006-07-10 | 2013-10-23 | ペーベーアードライ ビオメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗菌ペプチド |
| GB0724951D0 (en) * | 2007-12-20 | 2008-01-30 | Lytix Biopharma As | Compounds |
| ATE482186T1 (de) * | 2008-03-18 | 2010-10-15 | Univ Dresden Tech | Modulares gerüst zur gestaltung von spezifischen molekülen zur verwendung als pepitmimetika und hemmer für die proteininteraktion |
-
2009
- 2009-11-02 GB GBGB0919194.1A patent/GB0919194D0/en not_active Ceased
-
2010
- 2010-11-02 WO PCT/GB2010/002024 patent/WO2011051692A1/en not_active Ceased
- 2010-11-02 BR BR112012010333A patent/BR112012010333A2/pt active IP Right Grant
- 2010-11-02 NZ NZ599791A patent/NZ599791A/en unknown
- 2010-11-02 US US13/505,625 patent/US8809280B2/en active Active
- 2010-11-02 CA CA2777749A patent/CA2777749C/en active Active
- 2010-11-02 JP JP2012535924A patent/JP5810090B2/ja active Active
- 2010-11-02 RU RU2012121264/04A patent/RU2548905C2/ru active
- 2010-11-02 AU AU2010311186A patent/AU2010311186B2/en active Active
- 2010-11-02 EP EP10784830.1A patent/EP2496596B1/en active Active
- 2010-11-02 DK DK10784830.1T patent/DK2496596T3/en active
- 2010-11-02 RU RU2015111706A patent/RU2676713C2/ru active
- 2010-11-02 PL PL10784830T patent/PL2496596T3/pl unknown
- 2010-11-02 KR KR1020127014266A patent/KR101730680B1/ko active Active
- 2010-11-02 CN CN201080049560.6A patent/CN102762586B/zh active Active
- 2010-11-02 ES ES10784830.1T patent/ES2621188T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| DK2496596T3 (en) | 2017-04-03 |
| EP2496596A1 (en) | 2012-09-12 |
| JP2013509389A (ja) | 2013-03-14 |
| CA2777749C (en) | 2019-08-06 |
| ES2621188T3 (es) | 2017-07-03 |
| GB0919194D0 (en) | 2009-12-16 |
| JP5810090B2 (ja) | 2015-11-11 |
| RU2015111706A3 (enExample) | 2018-10-29 |
| RU2548905C2 (ru) | 2015-04-20 |
| US20130035296A1 (en) | 2013-02-07 |
| KR20120104986A (ko) | 2012-09-24 |
| AU2010311186B2 (en) | 2015-09-24 |
| RU2676713C2 (ru) | 2019-01-10 |
| RU2012121264A (ru) | 2013-12-10 |
| WO2011051692A1 (en) | 2011-05-05 |
| CN102762586A (zh) | 2012-10-31 |
| CN102762586B (zh) | 2016-10-05 |
| PL2496596T3 (pl) | 2017-08-31 |
| AU2010311186A1 (en) | 2012-05-31 |
| US8809280B2 (en) | 2014-08-19 |
| KR101730680B1 (ko) | 2017-04-26 |
| NZ599791A (en) | 2014-10-31 |
| RU2015111706A (ru) | 2015-11-10 |
| EP2496596B1 (en) | 2017-01-11 |
| CA2777749A1 (en) | 2011-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012010333A2 (pt) | peptídeos terapêuticos | |
| Zhou et al. | Reactive oxygen species scavengers ameliorate mechanical allodynia in a rat model of cancer-induced bone pain | |
| Kim et al. | Amelioration of Alzheimer’s disease by neuroprotective effect of sulforaphane in animal model | |
| BR112017024777A2 (pt) | uso de uma composiçao farmacêutica e de um antibiótico não absorvível para tratamento de transtorno do espectro autista referência cruzada a pedidos relacionados? | |
| BR112015012366A8 (pt) | antagonistas de cxcr7, uso dos mesmos, composição farmacêutica, bem como métodos para detectar níveis elevados de cxcr7 em uma amostra e para imagear um tumor, órgão, ou tecido | |
| BR112012018500A2 (pt) | alguns inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso destas | |
| BR112012024379A2 (pt) | "peptídeos glucagon, seu uso, bem como composição farmacêutica" | |
| BR112022022524A2 (pt) | Proteínas imunomoduladoras inibidoras de april e baff com e sem uma proteína inibidora de células t e métodos de uso das mesmas | |
| BR112015028278A2 (pt) | processo para a preparação de eritrócitos carregados com uma ou mais substâncias de interesse farmacêutico e eritrócitos assim obtidos | |
| BR112017019779A2 (pt) | composto, e, composição farmacêutica | |
| BR112014032999A2 (pt) | optimização de anticorpos que ligam o gene de ativação de linfócito 3 (lag-3), e uso dos mesmos | |
| BR112012001984B8 (pt) | anticorpos humanos com alta afinidade para angiopoietina-2 humana, uso dos mesmos e composição farmacêutica | |
| CO6390113A2 (es) | Composición farmacéutica | |
| BR112016002753A2 (pt) | anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos | |
| EA201590709A1 (ru) | Комбинированная терапия и ее применение для лечения димиелинизирующих расстройств | |
| BR112012029975A2 (pt) | peptídeo como medicamento, em particular para o tratamento do câncer. | |
| BR112017001010A2 (pt) | inibidores peptídicos orais do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias intestinais | |
| BR112014023384A8 (pt) | inibidores de bace espirocíclicos de di-hidro-tiazina e di-hidro-oxazina, e composições e usos dos mesmos. | |
| BR112016012538A2 (pt) | peptídeos citotóxicos e conjugados dos mesmos | |
| BR112014018728A8 (pt) | Compostos de purinonas como inibidores de quinase | |
| CO6390070A2 (es) | Terapeuticos dirigidos a base de proteinas manipuladas para receptores de tirosina cinasas incluyendo receptor de factor de crecimiento tipo insulina -i | |
| BRPI0717156B8 (pt) | inibidores do co-transportador 2 da glicose de sódio e composição farmacêutica que os compreende | |
| BR112012014180A2 (pt) | composto, composição farmacêutica, uso da composição farmacêutica, e, método para tratar uma doença ou em distúrbio. | |
| BR112012006501A8 (pt) | Polipeptídios e usos dos mesmos | |
| BR112017026287A2 (pt) | composições de hidroxipropil beta-ciclodextrina e métodos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/11/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |